The most recent advances in understanding and managing hidradenitis suppurativa [version 1; peer review: 2 approved]

Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members an...

Full description

Saved in:
Bibliographic Details
Published in:F1000 research 2020, Vol.9, p.1049
Main Authors: Narla, Shanthi, Lyons, Alexis B, Hamzavi, Iltefat H
Format: Article
Language:English
Subjects:
Anemia
Clinical trials
Cyclin-dependent kinases
Diabetes
Diet
Fatty acids
Females
Fibroblasts
Inflammation
Kinases
Males
Minority & ethnic groups
Monoclonal antibodies
Neutrophils
Pathogenesis
Patients
Pediatrics
Pregnancy
Proteins
Puberty
Quality of life
Review
Skin
Skin diseases
TNF inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle unit that typically develops after puberty. HS has a significant negative impact on both the quality of life (QOL) of patients affected by this disease as well as family members and caregivers. However, the pathogenesis of HS is multifactorial and still remains to be fully elucidated, which makes the development of treatments difficult. The last 10 years have seen a surge in HS research, and many new findings have come to light, yet much more remains to be elucidated. Physicians must employ a multidisciplinary approach to maximally address all facets of HS. Clinical characteristics of the disease that differ between females and males as well as across different races and ethnic groups must be considered. Targeted topical, oral, and injectable therapies continue to be developed for HS as a greater understanding of the pathogenesis is reached. However, randomized controlled trials regarding dietary factors that may contribute to HS are needed to meet our patients' growing concerns and questions about the role of diet in HS pathogenesis. Finally, improved outcome measures are needed to standardize HS severity and grading between physicians and clinical trials, and a more diverse representation of HS populations is needed in clinical trials.
ISSN:2046-1402
2046-1402
DOI:10.12688/f1000research.26083.1